<DOC>
	<DOC>NCT00379990</DOC>
	<brief_summary>This is an exploratory study to examine the effect of iNOS inhibition in rheumatoid arthritis patients. The study involves 28 days repeat dosing with GW274150 (dose determined by the results from a previous study), prednisolone (7.5mg) or placebo.</brief_summary>
	<brief_title>A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of rheumatoid arthritis according to the revised 1987 criteria of the American College of Rheumatology Female subjects who are not capable of becoming pregnant Active disease defined as Disease Activity Score (DAS) 28 = 4.0 and at least one metacarpalphalangeal finger (MCP) joint with either detectable vascularity or thickness Stable doses of disease modifying antirheumatic drugs (DMARDs), (which can include but is not restricted to methotrexate, sulphasalazine and hydroxychloroquine in any combination) for 8 weeks prior to enrollment Patients receiving methotrexate must be on stable folate supplements Must have been on stable doses for 2 weeks prior to screening if using COX inhibitors Signed consent form The patient is able to understand and comply with protocol requirements, instructions and protocolstated restrictions Exclusion criteria: The subject is using, or has used, oral glucocorticoids within 8 weeks of enrollment The subject is currently receiving antirheumatic biological therapy (e.g. infliximab, adalimumab, etanercept or anakinra) The subject received their final dose of infliximab or adalimumab within 3 months of enrollment The subject received their final dose of etanercept or anakinra within 1 month of enrollment The subject has received another investigational drug within 30 days The subject drinks more than 28 units (male) or 21 units (female) of alcohol in a week History of liver or renal disease in the 6 months prior to screening The subject has a history of drug or other allergy Subject is positive for Hepatitis B and C or HIV virus The subject has positive pregnancy test The subject has positive test for drugs of abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>iNOS</keyword>
	<keyword>Exhaled NO</keyword>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>